Figure 1.
Kinetics of anti-RBD Abs and spike-specific T-cell response in patients with TDT compared with control subjects. (A) Comparison between health care workers (HCWs; open circles) and patients with transfusion-dependent β-thalassemia (TDT; red circles) naïve to SARS-CoV-2 at each sampling time. (B) Spike-specific T cells (measured by interferon (IFN) γ release after specific stimulation) in the peripheral blood of control HCWs (open circles) and patients with TDT (red circles) measured at the indicated time points. (C) Correlation between anti–spike RBD antibodies and age in patients with TDT and healthy subjects (HCWs) naïve to SARS-CoV-2. T0, before vaccination; T1, 2 weeks after the second dose; T2, 12 weeks after the second dose; T3, before the third dose; T4, 4 weeks after the third dose; T5, 12 weeks after the third dose; Rp, Pearson’s correlation coefficient.

Kinetics of anti-RBD Abs and spike-specific T-cell response in patients with TDT compared with control subjects. (A) Comparison between health care workers (HCWs; open circles) and patients with transfusion-dependent β-thalassemia (TDT; red circles) naïve to SARS-CoV-2 at each sampling time. (B) Spike-specific T cells (measured by interferon (IFN) γ release after specific stimulation) in the peripheral blood of control HCWs (open circles) and patients with TDT (red circles) measured at the indicated time points. (C) Correlation between anti–spike RBD antibodies and age in patients with TDT and healthy subjects (HCWs) naïve to SARS-CoV-2. T0, before vaccination; T1, 2 weeks after the second dose; T2, 12 weeks after the second dose; T3, before the third dose; T4, 4 weeks after the third dose; T5, 12 weeks after the third dose; Rp, Pearson’s correlation coefficient.

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal